About this document

ANDEMBRY: HAE Treatment Overview by greshiglesias999 is a document available to read on EtoBox.

ANDEMBRY (garadacimab-gxii) is a monoclonal antibody indicated for the prophylaxis of hereditary angioedema (HAE) in patients aged 12 and older, with an initial loading dose of 400 mg followed by 200 mg monthly. The most common adverse reactions include nasopharyngitis and abdominal pain, with no reported contraindications or significant warnings. It is available in prefilled autoinjectors and syringes for subcutaneous administration, and patients may self-administer after proper training.

Author

greshiglesias999

Language

EN